Anti-Human IL-13 (Tralokinumab) – Fc Muted™

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tralokinumab. CAT-354 (Tralokinumab) specifically binds to the type 2 cytokine IL-13.

IL-13 is an important mediator of allergic inflammation and disease¹ that plays a role in the regulation of IgE synthesis, induction of adhesion molecules, and chemokine expression². The functions of IL-13 overlap considerably with those of IL-4¹. IL-13 induces its effects through a multi-subunit receptor composed of the alpha chain of the IL-4 receptor (IL-4Rα) and an IL-13 binding subunit IL-13Rα1. IL-13 induces many features of allergic lung disease, including airway hyper-responsiveness, goblet cell metaplasia, and mucus hypersecretion, which all contribute to airway obstruction. IL-13 is also associated with the induction of chronic pulmonary eosinophilia and eosinophilic esophagitis³ and plays a key role in the pathogenesis of atopic dermatitis⁴. Although IL-13 is associated primarily with the induction of airway disease, it also has anti-inflammatory properties¹.

CAT-354 (Tralokinumab) was isolated and optimized using antibody display technologies³. Tralokinumab acts as a neutralizing antibody² that binds specifically and with high affinity to IL- 13, preventing interaction with the IL-13 receptor⁴. In mice administered human IL-13, tralokinumab blocks human IL-13-induced lung eosinophilia, significantly decreases airway hyper-responsiveness, and inhibits eosinophil recruitment to the esophagus³. Tralokinumab does not affect human IL-13-induced goblet cell metaplasia in mouse lungs. Additionally, phase 3 trials produced inconsistent benefits for the treatment of asthma and clinical evaluation was discontinued for this indication⁴.

Tralokinumab has been studied and approved for use in atopic dermatitis⁴.

IL-13 is a cytokine secreted by many cell types but especially T helper type 2 (Th2) cells.

IL-4Rα, IL13RA1, IL13RA2

1 Wynn, TA. et al. (2003) Annu Rev Immunol. 21: 425
2 Kaur D, Hollins F, Woodman L, et al. Allergy. 61(9):1047-1053. 2006.
3 Blanchard C, Mishra A, Saito-Akei H, et al. Clin Exp Allergy. 35(8):1096-1103. 2005.
4 Duggan S. Drugs. 81(14):1657-1663. 2021.
5 Oh CK, Faggioni R, Jin F, et al. Br J Clin Pharmacol. 69(6):645-55. 2010.
6 Singh D, Kane B, Molfino NA, et al. BMC Pulm Med. 10:3. 2010.